

Research Grade Aducanumab

Summary

Catalog No.	DHC12504
Alternative Names	BART, BIIIB-037, CAS: 1384260-65-4
Clone ID	Aducanumab
Host species	Human
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Concentration	2.3 mg/ml
Purity	>95% as determined by SDS-PAGE.
Clonality	Monoclonal
Isotype	IgG1-kappa
Applications	Research Grade Biosimilar
Target	AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50
Purification	Protein A/G purified from cell culture supernatant.


Recombinant Proteins & Antibodies

Endotoxin level	Please contact with the lab for this information.
Expression system	Mammalian Cells
Accession	P05067
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Note	For research use only. Not suitable for clinical or therapeutic use.

Description


Aducanumab (brand name: Aduhelm) is an amyloid beta-directed monoclonal antibody that targets amyloid beta in the brains of people with Alzheimer's to reduce its buildup. Aducanumab is a monoclonal antibody (a protein that helps your immune system target other proteins), and it is designed to help your body remove something called amyloid beta from the brain. Amyloid beta is an important protein involved in the progression of Alzheimer's disease. Aducanumab is given intravenously (infused through a vein) monthly. Aducanumab does not cure Alzheimer's disease, but one (of two) large clinical studies suggests that aducanumab may slow the progression of the earliest symptoms of Alzheimer's disease.

Data Image



SDS PAGE for Aducanumab

SDS-PAGE



The purity of this product is >95% as determined by SEC-HPLC.

SEC-HPLC